Abstract: Invented are methods of transporting quantities of potassium clavulanate. Also invented are methods of forming a uniform continuous waxy barrier around medicament particles.

Abstract: Invented are controlled release formulations of medicaments for oral administration comprising a hydrophobic waxy material and prepared by thermal infusion.

Abstract: Human HBMBU14 polypeptides and DNA (RNA) encoding such HBMBU14 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such HBMBU14 for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 and HIV-2, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, atherosclerosis, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourette's syndrome, among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.

Abstract: Benign prostatic hypertrophy specific polynucleotides and polypeptides are provided. Methods of diagnosing benign prostatic hypertrophy using these polynucleotides and polypeptides are also provided. Human BPH1 polypeptides and DNA (RNA) encoding such BPH1 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such BPH1 for the treatment of prostate disease. Antagonists against such BPH1 and their use as a therapeutic to treat prostate disease are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the BPH1 and for detecting altered levels of the polypeptide in a host.

Abstract: Novel indane and indene derivatives are described which are endothelin receptor antagonists.

Abstract: This invention relates to nucleic acid sequences conserved in strains of yeasts. More particularly, this invention relates to segments of the ALS1 gene of Candida albicans useful as probes and primers for the identification of yeast, particularly Candida, infections.

Abstract: This invention relates to a polymer-based cleanser for superficial and deep cleansing of skin.

Abstract: NK.sub.3 receptor antagonists of formula (I): ##STR1## are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.

Abstract: An oral liquid pharmaceutical composition comprising a paroxetine-Amberlite IRP88 complex.

Abstract: Two-component pharmaceutical compositions for topical application to the human or animal body and intended for mixing together on or immediately prior to application, comprising two liquid phases having different lipophilicities and a drug dissolved in at least one of the liquid phases.

Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R.sub.1 represents (a) in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; and R.sub.3 is CN; said process comprising reacting a compound of formula (II) wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.

Abstract: Saliva binding protein polypeptides and DNA (RNA) of Staphylococcus aureus encoding such saliva binding protein and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such saliva binding protein for the treatment of infection, particularly bacterial infections. Antagonists against such saliva binding protein and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of saliva binding protein nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding saliva binding protein family and for detecting the polypeptide in host.

Abstract: A compound of formula (I) or a salt thereof: ##STR1## wherein P is a 5 to 7 membered heterocyclic ring selected from the group consisting of thienyl, furyl, pyrrolyl, triazolyl, diazolyl, tetrazolyl, imidazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimdyl and pyrazinyl;R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkenyl, C.sub.1-6 alkoxy, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkylOC.sub.1-6 alkyl, alkanoyl, optionally substituted phenyl, alkanoyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO.sub.2 R.sup.9,CONR.sup.10 R.sup.11 where R.sup.9, R.sup.10 and R.sup.11 are independently hydrogen or C.sub.1-6 alkyl;R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-6 alkyl;R.sup.6 is hydrogen, halogen, hydroxy, C.sub.1-6 alkyl or C.sub.1-6 alkoxyR.sup.7 and R.sup.8 are independently hydrogen, C.sub.

Abstract: A DNA encoding a 16 kD protein capable of inducing an immune response protective against human malarial infection caused by Plasmodium falciparum, and to the cloning and expression of a gene encoding the said protein. The invention further relates to novel vaccines comprising the said protein and to their use in the vaccination of humans at risk from malaria.

Abstract: This invention relates to a novel protein capable of inducing an immune response protective against human malarial infection caused by Plasmodium falciparum, and to the cloning and expression of a gene encoding the said protein. The invention further relates to novel vaccines comprising the said protein and to their use in the vaccination of humans at risk from malaria.

Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.

Abstract: This invention relates to certain 1,3,3-(trisubstituted)cyclohex-1-ene dimers and related compounds which are useful in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Abstract: This invention relates to novel compounds which inhibit platelet aggregation, pharmaceutical compositions containing the compounds, and methods of using the compounds.